p.104 抽出テキスト

428. Al-Mallah MH, Dilsizian V. The impact of revascularization on mortality: a debate on patient selection bias vs entry bias. J Am Coll Cardiol 2022;80:216–8. https://doi.org/ 10.1016/j.jacc.2022.04.051 429. Adjedj J, De Bruyne B, Floré V, Di Gioia G, Ferrara A, Pellicano M, et al. Significance of intermediate values of fractional flow reserve in patients with coronary artery disease. Circulation 2016;133:502–8. https://doi.org/10.1161/circulationaha.115.018747 430. Fournier S, Collet C, Xaplanteris P, Zimmermann FM, Toth GG, Tonino PAL, et al. Global fractional flow reserve value predicts 5-year outcomes in patients with coronary atherosclerosis but without ischemia. J Am Heart Assoc 2020;9:e017729. https://doi. org/10.1161/jaha.120.017729 431. Lee JM, Koo BK, Shin ES, Nam C-W, Doh J-H, Hwang D, et al. Clinical implications of three-vessel fractional flow reserve measurement in patients with coronary artery disease. Eur Heart J 2018;39:945–51. https://doi.org/10.1093/eurheartj/ehx458 432. Collet C, Miyazaki Y, Ryan N, Asano T, Tenekecioglu E, Sonck J, et al. Fractional flow reserve derived from computed tomographic angiography in patients with multivessel CAD. J Am Coll Cardiol 2018;71:2756–69. https://doi.org/10.1016/j.jacc.2018.02.053 433. Asano T, Katagiri Y, Chang CC, Kogame N, Chichareon P, Takahashi K, et al. Angiography-derived fractional flow reserve in the SYNTAX II trial: feasibility, diagnostic performance of quantitative flow ratio, and clinical prognostic value of functional SYNTAX score derived from quantitative flow ratio in patients with 3-vessel disease. JACC Cardiovasc Interv 2019;12:259–70. https://doi.org/10.1016/j.jcin.2018.09.023 434. Zhang R, Song C, Guan C, Liu Q, Wang C, Xie L, et al. Prognostic value of quantitative flow ratio based functional SYNTAX score in patients with left main or multivessel coronary artery disease. Circ Cardiovasc Interv 2020;13:e009155. https://doi.org/10. 1161/circinterventions.120.009155 435. Shaw LJ, Berman DS, Picard MH, Friedrich MG, Kwong RY, Stone GW, et al. Comparative definitions for moderate-severe ischemia in stress nuclear, echocardiography, and magnetic resonance imaging. JACC Cardiovasc Imaging 2014;7:593–604. https://doi.org/10.1016/j.jcmg.2013.10.021 436. Anderson L, Brown JP, Clark AM, Dalal H, Rossau HKK, Bridges C, et al. Patient education in the management of coronary heart disease. Cochrane Database Syst Rev 2017; 6:CD008895. https://doi.org/10.1002/14651858.CD008895.pub3 437. Collado-Mateo D, Lavin-Perez AM, Penacoba C, Del Coso J, Leyton-Román M, Luque-Casado A, et al. Key factors associated with adherence to physical exercise in patients with chronic diseases and older adults: an umbrella review. Int J Environ Res Public Health 2021;18:2023. https://doi.org/10.3390/ijerph18042023 438. Kohler AK, Jaarsma T, Tingstrom P, Nilsson S. The effect of problem-based learning after coronary heart disease—a randomised study in primary health care (COR-PRIM). BMC Cardiovasc Disord 2020;20:370. https://doi.org/10.1186/s12872- 020-01647-2 439. Alzaman N, Wartak SA, Friderici J, Rothberg MB. Effect of patients’ awareness of CVD risk factors on health-related behaviors. South Med J 2013;106:606–9. https://doi.org/ 10.1097/SMJ.0000000000000013 440. Riegel B, Jaarsma T, Stromberg A. A middle-range theory of self-care of chronic illness. ANS Adv Nurs Sci 2012;35:194–204. https://doi.org/10.1097/ANS.0b013e318261b1ba 441. Astin F, Lucock M, Jennings CS. Heart and mind: behavioural cardiology demystified for the clinician. Heart 2019;105:881–8. https://doi.org/10.1136/heartjnl-2016-310750 442. Sheeran P, Harris PR, Epton T. Does heightening risk appraisals change people’s intentions and behavior? A meta-analysis of experimental studies. Psychol Bull 2014;140: 511–43. https://doi.org/10.1037/a0033065 443. Zwack CC, Smith C, Poulsen V, Raffoul N, Redfern J. Information needs and communication strategies for people with coronary heart disease: a scoping review. Int J Environ Res Public Health 2023;20:1723. https://doi.org/10.3390/ijerph20031723 444. Navar AM, Wang TY, Mi X, Robinson JG, Virani SS, Roger VL, et al. Influence of cardiovascular risk communication tools and presentation formats on patient perceptions and preferences. JAMA Cardiol 2018;3:1192–9. https://doi.org/10.1001/jamacardio. 2018.3680 445. Whitmore K, Zhou Z, Chapman N, Huynh Q, Magnussen CG, Sharman JE, et al. Impact of patient visualization of cardiovascular images on modification of cardiovascular risk factors: systematic review and meta-analysis. JACC Cardiovasc Imaging 2023;16: 1069–81. https://doi.org/10.1016/j.jcmg.2023.03.007 446. Rossello X, Dorresteijn JA, Janssen A, Lambrinou E, Scherrenberg M, Bonnefoy-Cudraz E, et al. Risk prediction tools in cardiovascular disease prevention: a report from the ESC Prevention of CVD Programme led by the European Association of Preventive Cardiology (EAPC) in collaboration with the Acute Cardiovascular Care Association (ACCA) and the Association of Cardiovascular Nursing and Allied Professions (ACNAP). Eur J Prev Cardiol 2019;26:1534–44. https://doi.org/10.1177/2047487319846715 447. Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev 2004:CD003041. https://doi.org/10.1002/ 14651858.CD003041.pub2 448. Barth J, Jacob T, Daha I, Critchley JA. Psychosocial interventions for smoking cessation in patients with coronary heart disease. Cochrane Database Syst Rev 2015;7: CD006886. https://doi.org/10.1002/14651858.CD006886.pub2 449. Prochaska JJ, Benowitz NL. The past, present, and future of nicotine addiction therapy. Annu Rev Med 2016;67:467–86. https://doi.org/10.1146/annurev-med-111314-033712 450. Suissa K, Lariviere J, Eisenberg MJ, Eberg M, Gore GC, Grad R, et al. Efficacy and safety of smoking cessation interventions in patients with cardiovascular disease: a network meta-analysis of randomized controlled trials. Circ Cardiovasc Qual Outcomes 2017;10: e002458. https://doi.org/10.1161/CIRCOUTCOMES.115.002458 451. Lindson N, Chepkin SC, Ye W, Fanshawe TR, Bullen C, Hartmann-Boyce J. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2019;4:CD013308. https://doi.org/10.1002/ 14651858.CD013308 452. Mills EJ, Thorlund K, Eapen S, Wu P, Prochaska JJ. Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. Circulation 2014;129:28–41. https://doi.org/10.1161/CIRCULATIONAHA.113.003961 453. Kavousi M, Pisinger C, Barthelemy JC, De Smedt D, Koskinas K, Marques-Vidal P, et al. Electronic cigarettes and health with special focus on cardiovascular effects: position paper of the European Association of Preventive Cardiology (EAPC). Eur J Prev Cardiol 2020;28:1552–66. https://doi.org/10.1177/2047487320941993 454. Qasim H, Karim ZA, Rivera JO, Khasawneh FT, Alshbool FZ. Impact of electronic cigarettes on the cardiovascular system. J Am Heart Assoc 2017;6:e006353. https://doi. org/10.1161/JAHA.117.006353 455. Hartmann-Boyce J, McRobbie H, Lindson N, Bullen C, Begh R, Theodoulou A, et al. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev 2020;10: CD010216. https://doi.org/10.1002/14651858.CD010216.pub4 456. Abu Jad AA, Ravanavena A, Ravindra C, Igweonu-Nwakile EO, Ali S, Paul S, et al. Adverse effects of cannabinoids and tobacco consumption on the cardiovascular system: a systematic review. Cureus 2022;14:e29208. https://doi.org/10.7759/cureus. 29208 457. Schwartz BG, Rezkalla S, Kloner RA. Cardiovascular effects of cocaine. Circulation 2010;122:2558–69. https://doi.org/10.1161/CIRCULATIONAHA.110.940569 458. Singleton JH, Abner EL, Akpunonu PD, Kucharska-Newton AM. Association of nonacute opioid use and cardiovascular diseases: a scoping review of the literature. J Am Heart Assoc 2021;10:e021260. https://doi.org/10.1161/JAHA.121.021260 459. DeFilippis EM, Bajaj NS, Singh A, Malloy R, Givertz MM, Blankstein R, et al. Marijuana use in patients with cardiovascular disease: JACC review topic of the week. J Am Coll Cardiol 2020;75:320–32. https://doi.org/10.1016/j.jacc.2019.11.025 460. McNeely J, Cleland CM, Strauss SM, Palamar JJ, Rotrosen J, Saitz R. Validation of selfadministered single-item screening questions (SISQS) for unhealthy alcohol and drug use in primary care patients. J Gen Intern Med 2015;30:1757–64. https://doi.org/10. 1007/s11606-015-3391-6 461. Khan SS, Ning H, Wilkins JT, Allen N, Carnethon M, Berry JD, et al. Association of body mass index with lifetime risk of cardiovascular disease and compression of morbidity. JAMA Cardiol 2018;3:280–7. https://doi.org/10.1001/jamacardio.2018.0022 462. Pack QR, Rodriguez-Escudero JP, Thomas RJ, Ades PA, West CP, Somers VK, et al. The prognostic importance of weight loss in coronary artery disease: a systematic review and meta-analysis. Mayo Clin Proc 2014;89:1368–77. https://doi.org/10.1016/j. mayocp.2014.04.033 463. Strelitz J, Lawlor ER, Wu Y, Estlin A, Nandakumar G, Ahern AL, et al. Association between weight change and incidence of cardiovascular disease events and mortality among adults with type 2 diabetes: a systematic review of observational studies and behavioural intervention trials. Diabetologia 2022;65:424–39. https://doi.org/10.1007/ s00125-021-05605-1 464. Rubino DM, Greenway FL, Khalid U, O’Neil PM, Rosenstock J, Sørrig R, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA 2022;327:138–50. https://doi.org/10.1001/jama.2021.23619 465. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023;389:2221–32. https://doi.org/10.1056/NEJMoa2307563 466. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022;387: 205–16. https://doi.org/10.1056/NEJMoa2206038 467. Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2023;402:613–26. https://doi.org/10.1016/S0140-6736(23)01200-X 468. Lopez-Jimenez F, Bhatia S, Collazo-Clavell ML, Sarr MG, Somers VK. Safety and efficacy of bariatric surgery in patients with coronary artery disease. Mayo Clin Proc 2005;80: 1157–62. https://doi.org/10.4065/80.9.1157 469. De Bacquer D, Jennings CS, Mirrakhimov E, Lovic D, Bruthans J, De Smedt D, et al. Potential for optimizing management of obesity in the secondary prevention of coronary heart disease. Eur Heart J Qual Care Clin Outcomes 2022;8:568–76. https://doi.org/ 10.1093/ehjqcco/qcab043 470. Wood AM, Kaptoge S, Butterworth AS, Willeit P, Warnakula S, Bolton T, et al. Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies. Lancet 2018;391:1513–23. https://doi.org/10.1016/S0140-6736(18)30134-X Downloaded from academic.oup.com/eurheartj/article/45/36/3415/7743115 by guest on 07 October 2026